Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Bevacizumab + Carboplatin + Paclitaxel
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bevacizumab Avastin VEGF Antibody 11 VEGFR Inhibitor (Pan) 36 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).
Carboplatin Paraplatin CBDCA Chemotherapy - Platinum 7 Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03556839 Phase III Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) Active, not recruiting USA | ITA | FRA | ESP | DEU 3
NCT03642132 Phase III Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Talazoparib Avelumab + Carboplatin + Paclitaxel + Talazoparib Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Terminated USA | ITA | BEL | AUS 6
NCT03462212 Phase Ib/II Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) Recruiting ITA 0
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 12
NCT01146795 Phase II Bevacizumab + Carboplatin + Paclitaxel Neoadjuvant Therapy for Ovarian Cancer Completed USA 0
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 12
NCT02810457 Phase III Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) Completed USA | ITA | ESP | DEU 20
NCT05183984 Phase II Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1) Recruiting FRA 1
NCT00976573 Phase II Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Everolimus + Paclitaxel Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Completed USA 0
NCT05009082 Phase III Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Recruiting DEU 0
NCT03740165 Phase III Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT03038100 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 14
NCT01239732 Phase III Bevacizumab + Carboplatin + Paclitaxel A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NLD | ITA | FRA | ESP | CAN | AUT 31
NCT02364999 Phase III Bevacizumab + Carboplatin + Paclitaxel A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC Completed USA | NLD | ITA | FRA | ESP | DEU | AUS 20
NCT05739981 Phase II Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD) Recruiting USA 0


Additional content available in CKB BOOST